[{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Reports Promising Interim Data From SPN-817 Epilepsy Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Fordine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Fordine
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target